Bunazosin
Trade name: detantol
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Oct 1, 2005 (NCT00130156)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Alpha-1 adrenergic receptorANTAGONIST
Alpha-1 adrenergic receptor antagonist
- Adrenergic receptor alpha-1ANTAGONIST
Adrenergic receptor alpha-1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1- Mol. weight
- 373.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL188185 ↗
Also known as
- 1h-1,4-diazepine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)hexahydro-4-(1-oxobutyl)-, monohydrochloride
- 4-amino-2-(4-butanoylhexahydro-1h-1,4-diazepin-1-yl)-6,7-dimethoxyquinazoline hcl
- andante
- bunazocine
- bunazosin
- bunazosin
- bunazosin
- bunazosin
- bunazosin
- bunazosin
- bunazosin
- bunazosin hcl
- bunazosin hcl
- bunazosin hcl
- bunazosin hydrochloride
- bunazosin hydrochloride
- bunazosin hydrochloride
- bunazosin hydrochloride
- bunazosin hydrochloride
- detantol
- e643
- e 643
- e-643
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00130156 | Phase 4 | Oct 1, 2005 | Eisai |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1